FindTrial
Sign In

CELLECTRA® 2000

DEVICE7 trials

Sponsors

Steven Deeks, Inovio Pharmaceuticals, University of Pennsylvania, International Vaccine Institute

Conditions

COVID-19 DiseaseCoronavirus InfectionHIV-1-infectionHealthy VolunteersLassa FeverSARS-CoV 2Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Phase 1

Therapeutic Vaccination in Treated HIV Disease
CompletedNCT03606213
Steven DeeksHIV-1-infection
Start: 2018-08-01End: 2021-05-17Updated: 2023-05-31
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
CompletedNCT03805984
Inovio PharmaceuticalsLassa Fever
Start: 2019-05-09End: 2020-10-21Updated: 2020-11-23
A Study of INO-A002 in Healthy Dengue Virus-naive Adults
CompletedNCT03831503
University of PennsylvaniaHealthy Volunteers
Start: 2019-02-07End: 2022-10-03Updated: 2023-12-14
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
CompletedNCT04336410
Inovio PharmaceuticalsCoronavirus Infection
Start: 2020-04-03End: 2022-02-10Updated: 2022-04-15
Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
CompletedNCT04447781
International Vaccine InstituteCoronavirus Infection, SARS-CoV 2
Start: 2020-07-15End: 2022-05-25Updated: 2022-07-18
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
WithdrawnNCT05430958
Inovio PharmaceuticalsCoronavirus Infection
Start: 2022-10-31End: 2024-03-31Updated: 2022-11-17

Phase 2

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
TerminatedNCT04642638
Inovio PharmaceuticalsCoronavirus Infection, COVID-19 Disease, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Start: 2020-11-30End: 2022-09-13Updated: 2023-12-20

Related Papers

Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial
BMC Infectious Diseases2025-05-25
Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial
Human Vaccines & Immunotherapeutics2025-01-266 citations
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
The Journal of Infectious Diseases2022-01-2459 citations
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Open Forum Infectious Diseases2021-11-012 citations
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.
2020-12-24202 citations
Understanding COVID-19 Vaccines and Their Development
Journal of Bone and Joint Surgery2020-07-316 citations
Are Genetic Vaccines the Right Weapon against COVID-19?
Molecular Therapy2020-06-0921 citations
Progress and Concept for COVID‐19 Vaccine Development
Biotechnology Journal2020-04-18115 citations